铂类新辅助化疗在三阴性乳腺癌中的系统综述与荟萃分析
该系统综述与荟萃分析纳入9项随机对照试验共2109例三阴性乳腺癌患者,评估铂类对比非铂类新辅助化疗的疗效与安全性。铂类方案显著提高病理完全缓解率(37.0%升至52.1%,OR 1.96,95%CI 1.46-2.62,P<0.001),但血液学3-4级不良事件风险显著增加,无事件生存和总生存无显著差异。
要点
- 铂类新辅助化疗显著提高三阴性乳腺癌病理完全缓解率(OR 1.96)。
- BRCA突变亚组中卡铂未显著提高病理完全缓解率(OR 1.17)。
- 铂类增加3-4级血液学毒性,但未增加神经毒性风险。
核心结论
- 在三阴性乳腺癌患者中,铂类新辅助化疗显著提高病理完全缓解率,但以更严重的血液学毒性为代价。
- 铂类新辅助化疗可作为三阴性乳腺癌患者的一种选择。
研究设计与样本
- 系统检索Medline、Web of Science及会议论文集至2017年10月30日,纳入比较铂类与非铂类新辅助化疗的随机对照试验。
- 共纳入9项随机对照试验,合计2109例三阴性乳腺癌患者。
主要发现
- 铂类新辅助化疗将病理完全缓解率从37.0%提高至52.1%(OR 1.96,95%CI 1.46-2.62,P<0.001)。
- 限定于3项使用相同标准方案(每周紫杉醇±卡铂序贯蒽环类和环磷酰胺)的随机对照试验(N=611),铂类仍显著提高病理完全缓解率(OR 2.53,95%CI 1.37-4.66,P=0.003)。
- 两项随机对照试验纳入的96例BRCA突变患者中,加用卡铂未显著提高病理完全缓解率(OR 1.17,95%CI 0.51-2.67,P=0.711)。
- 两项随机对照试验(N=748)报告生存结局,无事件生存(HR 0.72,95%CI 0.49-1.06,P=0.094)和总生存(HR 0.86,95%CI 0.46-1.63,P=0.651)均无显著差异。
- 铂类新辅助化疗显著增加3-4级血液学不良事件风险,但未增加3-4级神经毒性风险。
关键数值与推荐
- 病理完全缓解定义为ypT0/is pN0。
- 铂类新辅助化疗组病理完全缓解率为52.1%,非铂类组为37.0%(OR 1.96,95%CI 1.46-2.62,P<0.001)。
- BRCA突变亚组中卡铂对比非卡铂的病理完全缓解OR为1.17(95%CI 0.51-2.67,P=0.711)。
- 无事件生存HR为0.72(95%CI 0.49-1.06,P=0.094),总生存HR为0.86(95%CI 0.46-1.63,P=0.651)。
临床怎么用
- 对于三阴性乳腺癌患者,铂类新辅助化疗可作为提高病理完全缓解率的治疗选择。
- 应用铂类方案时需警惕3-4级血液学毒性风险增加。
- BRCA突变患者加用卡铂的病理完全缓解获益不显著,决策需个体化。
局限性
- 仅两项随机对照试验(N=748)报告生存结局,无事件生存和总生存差异未达统计学显著。
- BRCA突变亚组分析仅基于两项随机对照试验的96例患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines. Our meta-analysis aimed to better elucidate its activity, efficacy and safety. MATERIAL AND METHODS: A systematic search of Medline, Web of Science and conferences proceedings up to 30 October 2017 was carried out to identify randomized controlled trials (RCTs) investigating platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients. Using the fixed and random effects models, pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) were calculated for pathological complete response (pCR, defined as ypT0/is pN0), event-free survival (EFS), overall survival (OS) and grade 3 and 4 adverse events (AEs: neutropenia, anemia, thrombocytopenia and neuropathy). RESULTS: Nine RCTs (N = 2109) were included. Overall, platinum-based neoadjuvant chemotherapy significantly increased pCR rate from 37.0% to 52.1% (OR 1.96, 95% CI 1.46-2.62, P < 0.001). Platinum-based neoadjuvant chemotherapy remained significantly associated with increased pCR rate also after restricting the analysis to the three RCTs (N = 611) that used the same standard regimen in both groups of weekly paclitaxel (with or without carboplatin) followed by anthracycline and cyclophosphamide (OR 2.53, 95% CI 1.37-4.66, P = 0.003). Conversely, among the 96 BRCA-mutated patients included in two RCTs, the addition of carboplatin was not associated with significantly increased pCR rate (OR 1.17, 95% CI 0.51-2.67, P = 0.711). Two RCTs (N = 748) reported survival outcomes: no significant difference in EFS (HR 0.72, 95% CI 0.49-1.06, P = 0.094) and OS (HR 0.86, 95% CI 0.46-1.63, P = 0.651) was observed. A significant higher risk of grade 3 and 4 hematological AEs, with no increased risk of grade 3 and 4 neuropathy was observed with platinum-based neoadjuvant chemotherapy. CONCLUSION: In TNBC patients, platinum-based neoadjuvant chemotherapy is associated with significantly increased pCR rates at the cost of worse hematological toxicities. Platinum-based neoadjuvant chemotherapy may be considered an option in TNBC patients. PROSPERO REGISTRATION NUMBER: CRD42018080042.
引用
- Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018. PMID: 29873695. doi:10.1093/annonc/mdy127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。